Back to top
more

Eagle Pharmaceuticals (EGRX)

(Delayed Data from OTC)

$0.88 USD

0.88
9,005

+0.28 (45.83%)

Updated Oct 11, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.

Eagle Pharmaceuticals (EGRX) Beats Q3 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for October 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.

Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

Why Eagle Pharmaceuticals (EGRX) Might Surprise This Earnings Season

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cardinal Health (CAH) to Report Q3 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal third-quarter performance is likely to reflect solid performance in Pharmaceutical segment.

Trina Mukherjee headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.

Earnings Preview: Eagle Pharmaceuticals (EGRX) Q1 Earnings Expected to Decline

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eagle Pharmaceuticals (EGRX) Surpasses Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 37.14% and 8.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 17th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez

Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez

Nitish Marwah headshot

5 Momentum Picks Screened on Driehaus Strategy

Richard Herman Driehaus used the "buy high and sell higher" rule to create an investment approach.

Insulet (PODD) Catches Eye: Stock Jumps 8.9%

Insulet (PODD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.